
High-income countries gained the most economic value from COVID-19 vaccines but low-income countries got the most per-person vaccinations relative to GDP.
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.






